6 hydroxy 2 5 7 8 tetra methylchromane 2 carboxylic acid trolox

Ferlixit (62.5 mg/5 ml, sodium ferric gluconate complex in sucrose, SANOFI) and cisplatin (50 mg/100 ml, SANDOZ) were obtained from the outpatient pharmacy at the Unit of Gynecologic Oncology, Magna Graecia University of Catanzaro; deferoxamine mesylate salt (DFO), erastin, ferrostatin-1 (Fer-1), hemin and cloroquine (Cq) were purchased from Sigma Aldrich (Sigma-Aldrich, St. Louis, MO, USA); the antioxidant (±)-6-hydroxy-2,5,7,8-tetra-methylchromane-2-carboxylic acid (trolox) was ordered from Cayman Chemical (Cayman Chemical Company, Ann Arbor, USA). Cells were seeded in a 6-well plate in serum-free medium. Each compound was used at the following final concentrations: ferlixit at 100 µM and 250 µM for 1, 8, 24 or 48 h; cisplatin at 150 μM for 24 h; DFO at 200 µM for 24 h; erastin at 8 µM and 25 µM for 1, 8 or 24 h; Fer-1, hemin and Cq at 10 µM for 8, 24 or 48 h; and trolox at 200 μM for 8 h. Treatments were performed at least three times on independent biological replicates.

Ferlixit (62.5 mg/5 mL, SANOFI) was obtained from the outpatient pharmacy at Unit of Cardiology, Magna Graecia University, Germaneto, while the antioxidant (±)-6-hydroxy- 2,5,7,8-tetra-methylchromane-2-carboxylic acid (trolox) was ordered from Cayman Chemical (Cayman Chemical Company, Ann Arbor, United States). Cells were seeded in a 6-well plate in serum-free medium. Ferlixit was added into the medium at the final concentration of 250 µM for 24 h while trolox was used at 200 μM for 6 h.